Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC

Inclusion Criteria: * Age ≥ 18 years * PS:0-2 * Estimated life expectancy ≥ 6 months * Histologically confirmed diagnosis of squamous cell carcinoma of the head and neck * Target metastases can be treated in stereotactic radiotherapy * 1-3 synchronized metastases with unrestricted anatomic site * Greater cumulative diameter of synchronous metastases in once organ (liver, lung or brain) ≤ 6 cm with GTV = Clinical Target Volume (CTV) * Global maximum diameter (GTV) allowed for pulmonary oligometastases (less than 2 cm from the mediastinum), brain, node, is ≤ 3cm * Implementation of a method for taking into account movements and uncertainties (IGRT) for limiting the margin of CTV to PTV (PTV) so as not to exceed 7 cm large cumulative diameter of PTV * Performing a positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose (FDG-PET) 4 weeks before the inclusion * In case of cerebral metastases, MRI diagnostic is required * If locoregional disease is treated, controlled and non-progressive for more than three months (+/- 4 weeks) at baseline, synchronized initial tumor is possible * If metachronous metastases, locoregional disease previously treated should be monitored and considered not progressive for more than three months at baseline * In case of prior cancer other than HNSCC, complete remission for over 5 years is possible, any biopsy of metastases is left to the appreciation of referring physician * No chemotherapy or local treatment of metastases in the previous 6 mo…